UBS Group
AEON icon

UBS Group’s AEON Biopharma AEON Stock Holding History

UBS Group’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.12K Buy
4,182
+130
+3% +$145 ﹤0.01% 8985
2025
Q4 		$4.46K Buy
4,052
+2,860
+240% +$2.67K ﹤0.01% 8834
2025
Q3 		$964 Sell
1,192
-30,408
-96% -$23.4K ﹤0.01% 9480
2025
Q2 		$24K Buy
31,600
+28,643
+969% +$16.4K ﹤0.01% 8319
2025
Q1 		$1.72K Buy
2,957
+2,279
+336% +$16.2K ﹤0.01% 9460
2024
Q4 		$26.4K Sell
678
-122
-15% -$7.11K ﹤0.01% 7704
2024
Q3 		$60.5K Buy
+800
New +$70.4K ﹤0.01% 6690
2024
Q1 		– Sell
-9
Closed -$4.67K – 9237
2023
Q4 		$4.67K Buy
+9
New +$3.61K ﹤0.01% 7837
2023
Q1 		– Sell
-11
Closed -$8.06K – 9538
2022
Q4 		$8.06K Sell
11
-33
-75% -$23.6K ﹤0.01% 8822
2022
Q3 		$32K Buy
44
+29
+193% +$20.5K ﹤0.01% 6785
2022
Q2 		$11K Hold
15
– – ﹤0.01% 7777
2022
Q1 		$11K Buy
+15
New +$10.5K ﹤0.01% 8280

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group's AEON Position: Q1 2026 in Review

UBS Group increased its AEON Biopharma (AEON) stake by 3.2% in Q1 2026, buying an estimated $145 and bringing the position to 4,182 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #8985.

UBS Group first reported a position in AEON in Q1 2022 and has held it in 12 quarters since. The position peaked at $60.5K in Q3 2024. 24 funds tracked by Wall St. Rank hold AEON as of Q1 2026.

  • UBS Group held 4,182 shares of AEON Biopharma worth $4.12K as of Q1 2026.
  • UBS Group bought 130 AEON Biopharma shares in Q1 2026, an estimated $145.
  • AEON Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8985 holding.
  • UBS Group first reported a position in AEON Biopharma in Q1 2022 and has held it in 12 quarters since.
  • UBS Group's AEON Biopharma position peaked at $60.5K in Q3 2024.
  • 24 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.